

John M. Bergeron has been elected to the position of incoming president of the Human Proteomic Organization (HUPO). Dr. Bergeron's two-year term will begin in June 2004. He is professor and chair of the department of anatomy and cell biology at the Faculty of Medicine of McGill University, founder and scientific advisor of Caprion Pharmaceuticals and director of Genome Quebec/Genome Canada Montreal Proteome Center.

Michiel A. de Haan has resigned as vice chairman from the supervisory board of Crucell (Leiden, The Netherlands), a position he held since the company's incorporation in October 2000. He is the founder of Atlas Venture, where he served as managing partner from 1980 to 2000. He intends to devote more time to the support and financing of projects in developing countries, as a cofounder of the European Venture Philanthropy Association and a member of the advisory board of the Social Venture Capital Foundation.

Exelixis (S. San Francisco, CA, USA) has announced the departure of president of R&D and chief scientific officer **Geoffrey Duyk** at the end of the year in order to pursue other opportunities. Dr. Duyk joined Exelixis in April 1997 from Millennium Pharmaceuticals, where he was one of the founding scientific staff. **Frank McCormick**, a member of Exelixis' board and director of the University of California, San Francisco Comprehensive Cancer Center, will assume a senior advisory role in the company's R&D organization.

Amgen (Thousand Oaks, CA, USA) has named **H. Christian Fibiger** vice president and global therapeutic area head for neuroscience research, and **Paul G. Pearson** vice president of pharmacokinetics and drug metabolism. Dr. Fibiger comes to Amgen from Eli Lilly, where he served as vice president, neuroscience discovery research and clinical investigation, and vice president, Lilly Research Laboratories, Europe. Dr. Pearson was previously executive director, preclinical drug metabolism at Merck Research Laboratories.

Antigenics (New York) has appointed **Renu Gupta** senior vice president of development. Dr. Gupta was most recently vice president and head of US clinical research and development at Novartis. In her new position, she will be responsible for regulatory affairs, clinical development and program and portfolio management at Antigenics.



Paradigm Genetics (Research Triangle Park, NC, USA) has announced the resignation of chief scientific officer and vice president, business development **John E. Hamer**. Dr. Hamer will join merchant bank Burrill & Co.

Amylin Pharmaceuticals (San Diego) has named **Michael Hanley** vice president, discovery research. Dr. Hanley joined Amylin's scientific advisory board in 1992, and has served as a consultant for healthcare investors in the venture capital and banking communities and for companies such as Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals and Chiron.

NanoInk (Chicago) has named **Cédric Loiret-Bernal**, formerly CEO of GeneProt, as president and CEO as well as a member of the board of directors. Dr. Loiret-Bernal joins NanoInk from CDP Capital Technology Ventures, a Canadian institutional investor.

Vern Norviel has joined the law firm of Wilson Sonsini Goodrich & Rosati (Palo Alto, CA, USA) as a partner. Previously, he served as senior vice president and general counsel at Affymetrix, and was most recently general counsel and corporate secretary at Perlegen Sciences.

Sharan A. Pagano has been named vice president, business development & alliances at Genstruct (Cambridge, MA, USA). She joins the company from Proteome, where she served as senior director of business development and marketing. Previously, she held management positions in business development and strategic collaborations at Incyte.

Inovio (Oslo, Norway) has announced the appointment of **David J. Pyrce** to the position of chief business officer. Mr. Pyrce has previously served as vice president of corporate development at Vical and as a general partner with Bear Creek Capital Management.

Gualberto Ruaño, scientific founder and former chief executive of Genaissance Pharmaceuticals, has been named adjunct professor of biochemistry and molecular biology at the George Washington University School of Medicine and Health Sciences (Washington). He will serve as an advisor in the establishment of its McCormick Genomics Center, to be opened in 2004. Dr. Ruaño recently founded Genomas, another genomics company.